A New Hope for Cholangiocarcinoma Treatment

A New Hope for Cholangiocarcinoma Treatment

Cholangiocarcinoma (CCA), a deadly cancer originating from the biliary epithelium, has been a growing concern in recent years due to its increasing incidence and high mortality rates. With surgical resection being the primary curative option, many CCA patients face limited access to treatment. Furthermore, recurrence post-surgery and the limited effectiveness of systemic treatments have made it a pressing issue in oncology research. However, a recent study published in Clinical Epigenetics brings new hope to the fight against CCA by shedding light on the role of RSPO3 and DNA methylation in the progression of this aggressive cancer.

The research, conducted by Guanhua Wu, Da Wang, and their team from the Department of Biliary-Pancreatic Surgery at Tongji Hospital, Huazhong University of Science and Technology, reveals that RSPO3 plays a pivotal role in CCA and presents a novel avenue for targeted molecular therapy.

The study found that low expression of RSPO3 is associated with poorer survival rates in CCA patients. Digging deeper, the researchers discovered that the RSPO3 promoter DNA is hypermethylated in CCA, which is closely linked to the decreased RSPO3 expression. The balance between DNA methyltransferase DNMT3a and DNA demethylase TET1 significantly influences the expression of RSPO3 in CCA.

To further validate these findings, the team conducted both in vitro and in vivo experiments. They used dCas9DNMT3a to target RSPO3 promoter DNA methylation, which promoted the tumorigenicity of CCA. On the other hand, they used dCas9TET1CD to target RSPO3 promoter DNA demethylation, which inhibited CCA tumorigenicity. This suggests that the manipulation of RSPO3 expression through DNA methylation changes can have a direct impact on the progression of CCA.

In addition to these experiments, the study revealed that in a primary CCA model, knocking down Rspo3 accelerated CCA progression, while overexpression of Rspo3 inhibited it. These findings highlight the importance of RSPO3 in regulating CCA growth and underscore the potential for precision treatments by modulating its expression.

The implications of this research are significant. The study suggests that increased methylation and decreased expression of RSPO3 may serve as a prognostic marker for CCA. Restoring RSPO3 expression through targeted promoter DNA demethylation offers a promising avenue for more precise CCA treatment.

This breakthrough could provide much-needed hope for CCA patients who face limited treatment options. By understanding the role of RSPO3 and the influence of DNA methylation, researchers are paving the way for innovative therapies that target the root causes of CCA progression, potentially improving the prognosis and outcomes for patients with this challenging cancer.

In conclusion, the upregulation of RSPO3 via targeted promoter DNA demethylation opens new doors in the fight against cholangiocarcinoma. This research offers a glimmer of hope for the future, as it points to the possibility of more precise and effective treatments for this aggressive cancer, potentially saving lives and improving the quality of life for those affected by CCA.

 

CITATION:

Wu, G., Wang, D., Xiong, F., Liu, W., Wang, Q., Chen, J., Wang, B., & Chen, Y. (2023). Upregulation of RSPO3 via targeted promoter DNA demethylation inhibits the progression of Cholangiocarcinoma. Clinical Epigenetics, 15(1). https://doi.org/10.1186/s13148-023-01592-9

Back to blog

Leave a comment

Best Sellers